# Methodologies for developing national treatment guidelines

``` xml
<?xml version="1.0" encoding="UTF-8"?>
<GLOSSARY>
  <INFO>
    <NAME>Methodologies for developing national treatment guidelines</NAME>
    <INTRO>&lt;p dir=&quot;ltr&quot; style=&quot;text-align: left;&quot;&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.&lt;br&gt;&lt;/p&gt;</INTRO>
    <INTROFORMAT>1</INTROFORMAT>
    <ALLOWDUPLICATEDENTRIES>0</ALLOWDUPLICATEDENTRIES>
    <DISPLAYFORMAT>entrylist</DISPLAYFORMAT>
    <SHOWSPECIAL>1</SHOWSPECIAL>
    <SHOWALPHABET>1</SHOWALPHABET>
    <SHOWALL>1</SHOWALL>
    <ALLOWCOMMENTS>1</ALLOWCOMMENTS>
    <USEDYNALINK>1</USEDYNALINK>
    <DEFAULTAPPROVAL>1</DEFAULTAPPROVAL>
    <GLOBALGLOSSARY>0</GLOBALGLOSSARY>
    <ENTBYPAGE>10</ENTBYPAGE>
    <ENTRIES>
      <ENTRY>
        <CONCEPT>The FAO Action Plan on Antimicrobial Resistance 2021-2025</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot;&gt;FAO Conferences in 2015 and 2019 underscored the importance and
urgency of addressing the growing global threat of antimicrobial resistance
(AMR) in all countries through a coordinated, multisectoral, One Health approach in the context of the 2030 Agenda for Sustainable Development.&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;This &lt;a href=&quot;https://www.fao.org/3/cb5545en/cb5545en.pdf&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;FAO Action Plan on AMR 2021–2025&lt;/a&gt; sets out the five objectives that
guide the programming of FAO activities. The latter will be amended as needed to reflect progress, new challenges, and available
resources. The action plan principally is intended to help guide FAO’s
support to its Members to build capacities, and is not a policy document.
The Action Plan provides for flexibility to respond to Members’ requests and
participation of Members in activities indicated is voluntary. The activities and
support provided under the Action Plan will be guided by the latest developments in science, international guidance and standards.&lt;br /&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;The five key objectives to help focus efforts and accelerate progress are:&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;/p&gt;&lt;ol&gt;&lt;li&gt;Increasing stakeholder awareness and engagement&lt;/li&gt;&lt;li&gt;Strengthening surveillance and research&lt;/li&gt;&lt;li&gt;Enabling good practices&lt;/li&gt;&lt;li&gt;Promoting responsible use of antimicrobials&lt;/li&gt;&lt;li&gt;Strengthening governance and allocating resources sustainably&lt;/li&gt;&lt;/ol&gt;&lt;p&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;The Action Plan also includes a results chain and a detailed list of &lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;key activities to help guide the development and deployment of &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;NAPs to meet FAO Members’ needs.&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;FAO brings expertise in aquatic and terrestrial animal health and production, food and feed safety, genetic resources, crop production, natural &lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;resource management, risk communication and behavioural change. FAO &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;also supports regulatory frameworks, standards, target-setting, norm-setting and bottom-up processes of collective action.&lt;/span&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;FAO’s support to tackle AMR has gained momentum. This needs to be &lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;maintained and accelerated in order to coordinate the global response for &lt;/span&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;food and agriculture. Follow this link to open the complete document: &lt;/span&gt;&lt;a href=&quot;https://www.fao.org/3/cb5545en/cb5545en.pdf&quot; target=&quot;_blank&quot; style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;background-color:rgb(255,255,255);&quot; rel=&quot;noreferrer noopener&quot;&gt;&lt;span xml:lang=&quot;en-us&quot; lang=&quot;en-us&quot;&gt;https://www.fao.org/3/cb5545en/cb5545en.pdf&lt;/span&gt;&lt;/a&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>1</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <ALIASES>
          <ALIAS>
            <NAME>FAO</NAME>
          </ALIAS>
        </ALIASES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>FAO-USAD-GHSP Technical assistance for animal health systems to minimize the impacts of antimicrobial resistance in Asia</CONCEPT>
        <DEFINITION>&lt;h1&gt;&lt;b style=&quot;color: rgb(73, 80, 87); font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;Title of the project:&lt;/b&gt;&lt;span style=&quot;color: rgb(73, 80, 87); font-size: 1rem; font-weight: 400; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;&amp;nbsp;Technical assistance for animal health systems to minimize the impacts of antimicrobial resistance in Asia (OSRO/RAS/003/USA)&lt;/span&gt;&lt;br&gt;&lt;/h1&gt;

&lt;p&gt;&lt;b&gt;Status:&lt;/b&gt;&amp;nbsp;Ongoing&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Donor:&lt;/b&gt;&amp;nbsp;USA&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Focus&amp;nbsp;Countries&lt;/b&gt;:&amp;nbsp;Asian countries&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Period&lt;/b&gt;:&amp;nbsp;1 October 2020—30 September 2024&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Contact person (division):&amp;nbsp;&lt;/b&gt;Mary Joy&amp;nbsp;Gordoncillo&amp;nbsp;(RAP, ECTAD)&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Objectives&lt;/b&gt;:&amp;nbsp;Further enhance coordination and collaboration among AMR multi-sectoral stakeholders, increase institutional and multi-disciplinary AMR and AMU workforce capacity, promote preparedness and response of animal health systems, and increase adoption of good risk reduction practices along the value and supply chain.&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Outcomes and outputs:&lt;/b&gt;&amp;nbsp;&lt;/p&gt;
&lt;ul&gt;
    &lt;li&gt;&amp;nbsp;Outcome 1: Enhanced coordination and collaboration among multi-sectoral stakeholders&amp;nbsp;&lt;ul&gt;
            &lt;li&gt;Output 1.1: Multi-sectoral and multi-lateral coordination mechanisms are initiated, operationalized, and/or scaled up.&lt;/li&gt;
            &lt;li&gt;Output 1.2: AMR stakeholder engagement expanded and enhanced for actions.&lt;/li&gt;
        &lt;/ul&gt;
    &lt;/li&gt;
    &lt;li&gt;Outcome 2: Enhanced institutional and multi-disciplinary workforce capacity&lt;ul&gt;
            &lt;li&gt;Output 2.1: Multi-disciplinary workforce capacities on behavioural change, AMR surveillance, AMR governance and good practices are strengthened.&lt;/li&gt;
        &lt;/ul&gt;
    &lt;/li&gt;
    &lt;li&gt;Outcome 3: Enhanced preparedness and responses of animal health systems&lt;ul&gt;
            &lt;li&gt;Output 3.1: AMR surveillance in the region is expanded, sustained and progressively improved.&lt;/li&gt;
            &lt;li&gt;Output 3.2: AMR data management and utility towards evidence-based interventions is strengthened.&lt;/li&gt;
        &lt;/ul&gt;
    &lt;/li&gt;
    &lt;li&gt;Outcome 4: Increased adoption of good risk reduction practices along the value and supply chain&lt;ul&gt;
            &lt;li&gt;Output 4.1: Good farming practices for AMR risk reduction is strengthened, promoted and reinforced&amp;nbsp;&lt;/li&gt;
            &lt;li&gt;Output 4.2: Antimicrobial stewardship is strategically advocated.&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;br&gt;Direct link: https://www.fao.org/antimicrobial-resistance/projects/ongoing/project-9/en/&lt;br&gt;
&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
      </ENTRY>
      <ENTRY>
        <CONCEPT>PROTECT ME Responsible antibacterial use in the veterinary community</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;/p&gt;&lt;p&gt;BSAVA and SAMSoc have worked together to provide information that is intended to support practices in discussing and drawing up practice guidelines on responsible antibacterial use.&lt;/p&gt;&lt;p&gt;Antibacterial resistance is a politically important topic and there are those who wish to restrict veterinary use of certain antibacterial products, which could have significant implications for animal health and welfare. It is therefore essential that veterinary surgeons are seen to be using antibacterials responsibly.&lt;/p&gt;&lt;p&gt;The PROTECT ME poster, ‘no antibiotic required’ sample form and other supporting material are freely available to download from the&amp;nbsp;&lt;a href=&quot;https://www.bsavalibrary.com/content/book/10.22233/9781910443644&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;BSAVA Library here.&lt;/a&gt;&lt;/p&gt;Direct link: https://www.bsava.com/Resources/Veterinary-resources/PROTECT-ME/&lt;br&gt;&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <ALIASES>
          <ALIAS>
            <NAME>BSAVA, SAMSoc</NAME>
          </ALIAS>
        </ALIASES>
        <CATEGORIES>
          <CATEGORY>
            <NAME>PROTECT ME</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>GRADE Framework</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;/p&gt;
&lt;div&gt;
    &lt;p xml:lang=&quot;en-us&quot; lang=&quot;en-us&quot;&gt;&lt;span xml:lang=&quot;en-us&quot; lang=&quot;en-us&quot; style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;div&gt;
        &lt;div&gt;
            &lt;div&gt;
                &lt;p&gt;GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) is a transparent framework for developing and presenting summaries of evidence and provides a systematic approach for making clinical practice recommendations. It is the most widely adopted tool for grading the quality of evidence and for making recommendations with over 100 organisations worldwide officially endorsing GRADE. Follow this link to learn more about what GRADE is:&amp;nbsp;&amp;nbsp;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;https://bestpractice.bmj.com/info/toolkit/learn-ebm/what-is-grade/&lt;/span&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;
            &lt;/div&gt;
        &lt;/div&gt;
    &lt;/div&gt;
    &lt;p&gt;&lt;/p&gt;
&lt;/div&gt;&lt;br&gt;
&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>GRADE Framework</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>GRADE Online Learning Modules</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align: left;&quot;&gt;&lt;span data-contrast=&quot;auto&quot; xml:lang=&quot;EN-US&quot; lang=&quot;EN-US&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;These online learning modules are designed to help guideline developers and authors of systematic reviews learn how to use the GRADE approach to grade the evidence in systematic reviews, to create Summary of Findings Tables and GRADE Evidence Profiles, and move from evidence to making recommendations.&lt;/p&gt;&lt;p&gt;There are two sets of modules:&lt;/p&gt;&lt;ol&gt;&lt;li&gt;For authors of Cochrane systematic reviews and other systematic reviewers&lt;/li&gt;&lt;li&gt;For World Health Organization (WHO) guideline developers and other guideline developers&lt;/li&gt;&lt;/ol&gt;&lt;p&gt;Each module covers a specific topic related to GRADE and can be viewed in sequence as presented here or, depending on your learning needs, viewed in any order. Most modules are approximately 20 minutes or less and will open in an external video player tab when accessed through the links below.&lt;/p&gt;&lt;p&gt;Viewing is self-directed and anonymous. However, we welcome feedback. Please contact us with any comments.&lt;/p&gt;&lt;a href=&quot;https://cebgrade.mcmaster.ca/&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;&lt;span data-contrast=&quot;auto&quot; xml:lang=&quot;EN-US&quot; lang=&quot;EN-US&quot;&gt;https://cebgrade.mcmaster.ca/&lt;/span&gt;&lt;/a&gt;&lt;span data-contrast=&quot;auto&quot;&gt;&lt;/span&gt;&amp;nbsp;&lt;br&gt;&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>GRADE Framework</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>Guideline recommendations and antimicrobial resistance: the need for a change</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot;&gt;Abstract&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;Objectives: Antimicrobial resistance has become a global burden for which inappropriate antimicrobial use is an important contributing factor. Any decisions on the selection of antibiotics use should consider their effects on antimicrobial resistance. The objective of this study was to assess the extent to which antibiotic prescribing guidelines have considered resistance patterns when making recommendations for five highly prevalent infectious syndromes.&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;Design: We used Medline searches complemented with extensive use of Web engine to identify guidelines on empirical treatment of community-acquired pneumonia, urinary tract infections, acute otitis media, rhinosinusitis and pharyngitis. We collected data on microbiology and resistance patterns and identified discrete pattern categories. We assessed the extent to which recommendations considered resistance, in addition to efficacy and safety, when recommending antibiotics.&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;Results: We identified 135 guidelines, which reported a total of 251 recommendations. Most (103/135, 79%) were from developed countries. Community-acquired pneumonia was the syndrome mostly represented (51, 39%). In only 16 (6.4%) recommendations, selection of empirical antibiotic was discussed in relation to resistance and specific microbiological data. In a further 69 (27.5%) recommendations, references were made in relation to resistance, but the attempt was inconsistent. Across syndromes, 12 patterns of resistance with implications on recommendations were observed. 50% to 75% of recommendations did not attempt to set recommendation in the context of these patterns.&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;Conclusion: There is consistent evidence that guidelines on empirical antibiotic use did not routinely consider resistance in their recommendations. Decision-makers should analyse and report the extent of local resistance patterns to allow better decision-making.&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;Reference: Elias, C., Moja, L., Mertz, D., Loeb, M., Forte, G., &amp;amp; Magrini, N. (2017). Guideline recommendations and antimicrobial resistance: the need for a change.&amp;nbsp;&lt;i&gt;BMJ open&lt;/i&gt;,&amp;nbsp;&lt;i&gt;7&lt;/i&gt;(7), e016264. &lt;a href=&quot;https://doi.org/10.1136/bmjopen-2017-016264&quot; target=&quot;_blank&quot;&gt;https://doi.org/10.1136/bmjopen-2017-016264&lt;/a&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <ALIASES>
          <ALIAS>
            <NAME>Infection control, microbiology, protocols &amp; guidelines, public health, therapeutics</NAME>
          </ALIAS>
        </ALIASES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>Antimicrobial use Guidelines for Treatment of Respiratory Tract Disease in Dogs and Cats: Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot;&gt;Abstract&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;Respiratory tract disease can be associated with primary or secondary bacterial infections in dogs and cats and is a common reason for use and potential misuse, improper use, and overuse of antimicrobials. There is a lack of comprehensive treatment guidelines such as those that are available for human medicine. Accordingly, the International Society for Companion Animal Infectious Diseases convened a Working Group of clinical microbiologists, pharmacologists, and internists to share experiences, examine scientific data, review clinical trials, and develop these guidelines to assist veterinarians in making antimicrobial treatment choices for use in the management of bacterial respiratory diseases in dogs and cats.&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;Copyright © 2017 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.&lt;/span&gt;&lt;br&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;span style=&quot;font-size:1rem;font-family:&#039;Open Sans&#039;, &#039;-apple-system&#039;, BlinkMacSystemFont, &#039;Segoe UI&#039;, Roboto, &#039;Helvetica Neue&#039;, Arial, sans-serif, &#039;Apple Color Emoji&#039;, &#039;Segoe UI Emoji&#039;, &#039;Segoe UI Symbol&#039;;&quot;&gt;Reference:&amp;nbsp;Lappin, M. R., Blondeau, J., Boothe, D., Breitschwerdt, E. B., Guardabassi, L., Lloyd, D. H., Papich, M. G., Rankin, S. C., Sykes, J. E., Turnidge, J., &amp;amp; Weese, J. S. (2017). Antimicrobial use Guidelines for Treatment of Respiratory Tract Disease in Dogs and Cats: Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases.&amp;nbsp;&lt;i&gt;Journal of veterinary internal medicine&lt;/i&gt;,&amp;nbsp;&lt;i&gt;31&lt;/i&gt;(2), 279–294. &lt;a href=&quot;https://doi.org/10.1111/jvim.14627&quot; target=&quot;_blank&quot;&gt;https://doi.org/10.1111/jvim.14627&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <ALIASES>
          <ALIAS>
            <NAME>Bronchitis, Pneumonia, Pyothorax, Rhinitis, dogs, cats</NAME>
          </ALIAS>
        </ALIASES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>Developing, Implementing, and Monitoring the Use of Standard Treatment Guidelines: A SIAPS How-To Manual</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align: left;&quot;&gt;&lt;/p&gt;&lt;p&gt;Abstract&lt;/p&gt;&lt;p&gt;&lt;a href=&quot;https://siapsprogram.org/publication/stg-how-to-manual/&quot; target=&quot;_blank&quot;&gt;Developing,&amp;nbsp;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;Implementing, and&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;Monitoring the Use of&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;Standard Treatment&amp;nbsp;&lt;/span&gt;&lt;/a&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;&lt;a href=&quot;https://siapsprogram.org/publication/stg-how-to-manual/&quot; target=&quot;_blank&quot;&gt;Guidelines&lt;/a&gt;&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;are designed to assist healthcare professionals in making decisions about appropriate, effective patient care. However, health managers often have trouble setting and meeting the high standards required of modern, developed healthcare systems. With stakeholders expressing concern over issues such as strength of evidence, transparency, conflicts of interest, and effective implementation, it is clear that many healthcare professionals need further guidance in developing and making use of STGs.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;This manual&amp;nbsp;guides health professionals through the process of establishing and implementing STGs, placing special emphasis on the low- and middle-income country (LMIC) context. By including tools, templates, and success stories as well as hyperlinks to useful resources, the manual helps health practitioners understand not only important concepts of treatment guidelines, but also how they can best be used in practice.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Permanent link:&amp;nbsp;https://siapsprogram.org/publication/stg-how-to-manual/&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;https://siapsprogram.org/wp-content/uploads/2015/09/15-120-STG-How-to-Manual-09_01_20151.pdf&quot; target=&quot;_blank&quot;&gt;Developing, Implementing, and Monitoring the Use of Standard Treatment Guidelines: A SIAPS How-To Manual - View link&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;https://siapsprogram.org/wp-content/uploads/2015/09/15-120-STG-How-to-Manual-09_01_20151.pdf&quot; target=&quot;_blank&quot;&gt;Developing, Implementing, and Monitoring the Use of Standard Treatment Guidelines: A SIAPS How-To Manual - Download link&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;br&gt;&lt;br&gt;&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
      </ENTRY>
      <ENTRY>
        <CONCEPT>The Systematic Guideline Review: Method, rationale, and test on chronic heart failure</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot;&gt;Abstract&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;Background&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;Evidence-based guidelines have the potential to improve healthcare. However, their de-novo-development requires substantial resources – especially for complex conditions, and adaptation may be biased by contextually influenced recommendations in source guidelines. In this paper we describe a new approach to guideline development – the systematic guideline review method (SGR), and its application in the development of an evidence-based guideline for family physicians on chronic heart failure (CHF).&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;Methods&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;A systematic search for guidelines was carried out. Evidence-based guidelines on CHF management in adults in ambulatory care published in English or German between the years 2000 and 2004 were included. Guidelines on acute or right heart failure were excluded. Eligibility was assessed by two reviewers, methodological quality of selected guidelines was appraised using the AGREE instrument, and a framework of relevant clinical questions for diagnostics and treatment was derived. Data were extracted into evidence tables, systematically compared by means of a consistency analysis and synthesized in a preliminary draft. Most relevant primary sources were re-assessed to verify the cited evidence. Evidence and recommendations were summarized in a draft guideline.&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;Results&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;Of 16 included guidelines five were of good quality. A total of 35 recommendations were systematically compared: 25/35 were consistent, 9/35 inconsistent, and 1/35 un-rateable (derived from a single guideline). Of the 25 consistencies, 14 were based on consensus, seven on evidence and four differed in grading. Major inconsistencies were found in 3/9 of the inconsistent recommendations. We re-evaluated the evidence for 17 recommendations (evidence-based, differing evidence levels and minor inconsistencies) – the majority was congruent. Incongruity was found where the stated evidence could not be verified in the cited primary sources, or where the evaluation in the source guidelines focused on treatment benefits and underestimated the risks. The draft guideline was completed in 8.5 man-months. The main limitation to this study was the lack of a second reviewer.&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;Conclusion&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;The systematic guideline review including framework development, consistency analysis and validation is an effective, valid, and resource saving-approach to the development of evidence-based guidelines.&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;This article is available from &lt;a href=&quot;https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-9-74&quot; target=&quot;_blank&quot;&gt;https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-9-74&lt;/a&gt;&lt;br&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot;&gt;&lt;a href=&quot;https://bmchealthservres.biomedcentral.com/counter/pdf/10.1186/1472-6963-9-74.pdf&quot; target=&quot;_blank&quot;&gt;Download PDF&lt;/a&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
      </ENTRY>
      <ENTRY>
        <CONCEPT>WHO handbook for guideline development, 2nd Edition</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;/p&gt;&lt;h3&gt;&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3&gt;Overview&lt;/h3&gt;&lt;div title=&quot;Page 11&quot;&gt;&lt;div&gt;&lt;div&gt;&lt;p&gt;This handbook provides step-by-step guidance on how to plan, develop and publish a WHO guideline. It covers the methods, processes and procedures for producing a document that meets WHO standards. &lt;/p&gt;&lt;p&gt;Additional chapters of this handbook containing detailed guidance on selected topics are also available and new chapters will continue to be added.&lt;/p&gt;&lt;p&gt;&lt;a href=&quot;https://iris.who.int/bitstream/handle/10665/145714/9789241548960_eng.pdf?sequence=1&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;Download link&lt;/a&gt;&lt;br /&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Additional chapters&lt;/h3&gt;&lt;p&gt;&lt;strong&gt;Chapter 14:&lt;/strong&gt; &lt;a href=&quot;https://apps.who.int/iris/bitstream/handle/10665/145714/9789241548960_chap14_eng.pdf&quot;&gt;Strong recommendation when the evidence is low quality&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Chapter 15:&lt;/strong&gt; &lt;a href=&quot;https://apps.who.int/iris/bitstream/handle/10665/145714/9789241548960_chap15_eng.pdf&quot;&gt;Using evidence from qualitative research to develop WHO guidelines&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Chapter 16:&lt;/strong&gt; &lt;a href=&quot;https://apps.who.int/iris/bitstream/handle/10665/145714/9789241548960_chap16_eng.pdf&quot;&gt;Decision-making for guideline development at WHO&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Chapter 17: &lt;/strong&gt;&lt;a href=&quot;https://apps.who.int/iris/bitstream/handle/10665/145714/9789241548960-chap17-eng.pdf&quot;&gt;Developing guideline recommendations for tests or diagnostic tools&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Chapter 18:&lt;/strong&gt; &lt;a href=&quot;https://apps.who.int/iris/bitstream/handle/10665/145714/9789241548960-chap18-eng.pdf&quot;&gt;Incorporating a complexity perspective into WHO guidelines&lt;/a&gt;&lt;br /&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Supplement: &lt;/strong&gt;&lt;a href=&quot;https://www.who.int/publications-detail-redirect/WHO-SCI-QNS-MST-2023.1&quot;&gt;Criteria for use of evidence to inform recommendations&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;br /&gt;&lt;/div&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>Chinese</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>English</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>Appraisal of Guidelines for Research &amp; Evaluation Instrument (AGREE II)</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;&lt;/p&gt;&lt;p&gt;The Appraisal of Guidelines for Research &amp;amp; Evaluation Instrument (AGREE II) was developed to address the issue of variability in the quality of practice guidelines.&lt;/p&gt;&lt;p&gt;&lt;a href=&quot;https://www.agreetrust.org/wp-content/uploads/2017/12/AGREE-II-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf&quot; target=&quot;_blank&quot; rel=&quot;noreferrer noopener&quot;&gt;&lt;strong&gt;Download the PDF version of the AGREE II&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;&lt;p&gt;For more resources about the tool please select from the list below.&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;https://www.agreetrust.org/agree-ii-instructions/&quot;&gt;AGREE II Instructions&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;https://www.agreetrust.org/resource-centre/agree-ii-training-tools/&quot;&gt;AGREE II Training Tools&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;https://www.agreetrust.org/agree-ii-publications/&quot;&gt;AGREE II Publications&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;https://www.agreetrust.org/resource-centre/agree-ii/development-of-the-agree-ii/&quot;&gt;Development of the AGREE II&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;https://www.agreetrust.org/resource-centre/agree-ii/agree-ii-translations/&quot;&gt;AGREE II Translations&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href=&quot;https://www.agreetrust.org/resource-centre/agree-ii/faq-agree-ii-2/&quot;&gt;AGREE II FAQ&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;Link: https://www.agreetrust.org/resource-centre/agree-ii/&lt;br /&gt;&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>AGREE II Framework</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Chinese</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>English</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Japanese</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Korean</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>Thai</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>World Health Organization (WHO) guidelines on use of medically important antimicrobials in food-producing animals</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align: left;&quot;&gt;&lt;/p&gt;&lt;h2 id=&quot;Abs1&quot;&gt;Abstract&lt;/h2&gt;&lt;div id=&quot;Abs1-content&quot;&gt;&lt;h3 data-test=&quot;abstract-sub-heading&quot;&gt;Background&lt;/h3&gt;&lt;p&gt;Antimicrobial use in food-producing animals selects for antimicrobial resistance that can be transmitted to humans via food or other transmission routes. The World Health Organization (WHO) in 2005 ranked the medical importance of antimicrobials used in humans. In late 2017, to preserve the effectiveness of medically important antimicrobials for humans, WHO released guidelines on use of antimicrobials in food-producing animals that incorporated the latest WHO rankings.&lt;/p&gt;&lt;p&gt;Direct link:&amp;nbsp;&lt;a href=&quot;https://aricjournal.biomedcentral.com/articles/10.1186/s13756-017-0294-9&quot; target=&quot;_blank&quot;&gt;https://aricjournal.biomedcentral.com/articles/10.1186/s13756-017-0294-9&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href=&quot;https://aricjournal.biomedcentral.com/counter/pdf/10.1186/s13756-017-0294-9.pdf&quot; target=&quot;_blank&quot;&gt;Download PDF&lt;/a&gt;&lt;/p&gt;&lt;h3 data-test=&quot;abstract-sub-heading&quot;&gt;Methods&lt;/h3&gt;&lt;p&gt;WHO commissioned systematic reviews and literature reviews, and convened a Guideline Development Group (GDG) of external experts free of unacceptable conflicts-of-interest. The GDG assessed the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, and formulated recommendations using a structured evidence-to-decision approach that considered the balance of benefits and harms, feasibility, resource implications, and impact on equity. The resulting guidelines were peer-reviewed by an independent External Review Group and approved by the WHO Guidelines Review Committee.&lt;/p&gt;&lt;h3 data-test=&quot;abstract-sub-heading&quot;&gt;Results&lt;/h3&gt;&lt;p&gt;These guidelines recommend reductions in the overall use of medically important antimicrobials in food-producing animals, including complete restriction of use of antimicrobials for growth promotion and for disease prevention (i.e., in healthy animals considered at risk of infection). These guidelines also recommend that antimicrobials identified as critically important for humans not be used in food-producing animals for treatment or disease control unless susceptibility testing demonstrates the drug to be the only treatment option.&lt;/p&gt;&lt;h3 data-test=&quot;abstract-sub-heading&quot;&gt;Conclusions&lt;/h3&gt;&lt;p&gt;To preserve the effectiveness of medically important antimicrobials, veterinarians, farmers, regulatory agencies, and all other stakeholders are urged to adopt these recommendations and work towards implementation of these guidelines.&lt;/p&gt;&lt;/div&gt;&lt;br&gt;&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>English</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
          <CATEGORY>
            <NAME>WHO</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>Step-by-step approach for   development and implementation of   hospital antibiotic policy    and  standard treatment guidelines</CONCEPT>
        <DEFINITION>&lt;p style=&quot;text-align:left;&quot;&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;B4691.pdf&lt;/span&gt;&lt;br&gt;&lt;/p&gt;&lt;p style=&quot;text-align:left;&quot;&gt;&lt;span style=&quot;font-size: 1rem; font-family: &amp;quot;Open Sans&amp;quot;, -apple-system, BlinkMacSystemFont, &amp;quot;Segoe UI&amp;quot;, Roboto, &amp;quot;Helvetica Neue&amp;quot;, Arial, sans-serif, &amp;quot;Apple Color Emoji&amp;quot;, &amp;quot;Segoe UI Emoji&amp;quot;, &amp;quot;Segoe UI Symbol&amp;quot;;&quot;&gt;(PLEASE ADD ABSTRACT AND LINK)&lt;/span&gt;&lt;/p&gt;&lt;br&gt;&lt;br&gt;&lt;p&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
        <CATEGORIES>
          <CATEGORY>
            <NAME>WHO</NAME>
            <USEDYNALINK>1</USEDYNALINK>
          </CATEGORY>
        </CATEGORIES>
      </ENTRY>
      <ENTRY>
        <CONCEPT>ESGVM operating procedure for writing of veterinary  practice guidelines</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;(Please add abstract and link.)&lt;br&gt;&lt;/p&gt;&lt;p dir=&quot;ltr&quot; style=&quot;text-align:left;&quot;&gt;File name: ESGVM_Operating_Procedure_for_writing_Veterinary_Practice_Guidelines_-_April_3.2019.pdf&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
      </ENTRY>
      <ENTRY>
        <CONCEPT>ENOVAT Guidelines Core Group</CONCEPT>
        <DEFINITION>&lt;p dir=&quot;ltr&quot; style=&quot;text-align: left;&quot;&gt;Please update this entry. The title may be wrong.&lt;/p&gt;&lt;p dir=&quot;ltr&quot; style=&quot;text-align: left;&quot;&gt;File name: AMVBLfczST.pdf&lt;br&gt;&lt;/p&gt;</DEFINITION>
        <FORMAT>1</FORMAT>
        <USEDYNALINK>1</USEDYNALINK>
        <CASESENSITIVE>0</CASESENSITIVE>
        <FULLMATCH>0</FULLMATCH>
        <TEACHERENTRY>1</TEACHERENTRY>
      </ENTRY>
    </ENTRIES>
  </INFO>
</GLOSSARY>
```
